Open AccessDual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
Author(s) -
Chen Wang,
Kathy L. McGraw,
Amy F McLemore,
Rami S. Komrokji,
Ashley A. Basiorka,
Najla Al Ali,
Jeffrey E. Lancet,
Eric Padron,
Olivier Kosmider,
Michaëla Fontenay,
Pierre Fenaux,
Alan F. List,
David A. Sallman
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.278855
Subject(s) - lenalidomide , myelodysplastic syndromes , erythropoietin , medicine , anemia , cancer research , oncology , multiple myeloma , bone marrow
Not available.